JOP20190086A1 - مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب - Google Patents
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلبInfo
- Publication number
- JOP20190086A1 JOP20190086A1 JOP/2019/0086A JOP20190086A JOP20190086A1 JO P20190086 A1 JOP20190086 A1 JO P20190086A1 JO P20190086 A JOP20190086 A JO P20190086A JO P20190086 A1 JOP20190086 A1 JO P20190086A1
- Authority
- JO
- Jordan
- Prior art keywords
- arrhythmia
- treatment
- naphthyridinone derivatives
- present
- naphthyridinone
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title 1
- 230000006793 arrhythmia Effects 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يقدم الاختراع الحالي مركب بالصيغة (I) أو ملح مقبول صيدلانياً منها؛ حيث R1، R3-R6، X2 وX3 هي كما تم تعريفها في هذه الوثيقة، طريقة لتصنيع مركبات الاختراع، واستخداماتها العلاجية. يقدم الاختراع الحالي أيضاً توليفة من عوامل فعّالة صيدلانيًاً وتركيبة صيدلانية. صورة
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662410930P | 2016-10-21 | 2016-10-21 | |
CN2016102928 | 2016-10-21 | ||
US201662413292P | 2016-10-26 | 2016-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190086A1 true JOP20190086A1 (ar) | 2019-04-18 |
Family
ID=60409317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0086A JOP20190086A1 (ar) | 2016-10-21 | 2017-06-16 | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
Country Status (33)
Country | Link |
---|---|
US (3) | US10266531B2 (ar) |
EP (2) | EP4141006A1 (ar) |
JP (1) | JP7030802B2 (ar) |
KR (1) | KR102540872B1 (ar) |
CN (1) | CN109843887B (ar) |
AU (2) | AU2017344489C1 (ar) |
BR (1) | BR112019007863A2 (ar) |
CA (1) | CA3038624A1 (ar) |
CL (1) | CL2019001023A1 (ar) |
CO (1) | CO2019003894A2 (ar) |
CR (1) | CR20190201A (ar) |
CU (1) | CU24599B1 (ar) |
DO (1) | DOP2019000100A (ar) |
EC (1) | ECSP19026973A (ar) |
ES (1) | ES2934234T3 (ar) |
FI (1) | FI3529251T3 (ar) |
HR (1) | HRP20221516T1 (ar) |
HU (1) | HUE060882T2 (ar) |
IL (1) | IL266128B (ar) |
JO (1) | JOP20190086A1 (ar) |
LT (1) | LT3529251T (ar) |
MX (1) | MX2019004484A (ar) |
PE (1) | PE20190735A1 (ar) |
PH (1) | PH12019500849A1 (ar) |
PL (1) | PL3529251T3 (ar) |
PT (1) | PT3529251T (ar) |
RS (1) | RS63841B1 (ar) |
SA (1) | SA519401614B1 (ar) |
SG (1) | SG11201902529WA (ar) |
SI (1) | SI3529251T1 (ar) |
TW (1) | TWI759343B (ar) |
UY (1) | UY37445A (ar) |
WO (1) | WO2018073788A1 (ar) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
AU2019291792B2 (en) * | 2018-06-27 | 2022-09-29 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as T cell activators |
WO2022074567A1 (en) * | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I. Woodside Calif. Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
AU1625192A (en) | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
WO1996012704A1 (fr) | 1994-10-20 | 1996-05-02 | Wakunaga Seiyaku Kabushiki Kaisha | Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif |
ES2224235T3 (es) | 1996-04-19 | 2005-03-01 | Wakunaga Pharmaceutical Co., Ltd. | Nuevos derivados del acido piridonacarboxilico o sus sales y agentes antibacterianos que contienen los mismos como ingredientes activos. |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE69724140T2 (de) | 1996-11-28 | 2004-06-03 | Wakunaga Pharmaceutical Co., Ltd. | Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente |
WO1999064400A1 (en) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
CA2339484A1 (en) | 1998-08-03 | 2000-02-17 | Robert A. O'brien | Pyridinones for the treatment of sexual dysfunction |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6803388B2 (en) | 1999-09-23 | 2004-10-12 | Pfizer, Inc. | (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
EP1282410A2 (en) | 2000-04-12 | 2003-02-12 | Novartis AG | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
JP2003040866A (ja) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | N置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤 |
US6677352B1 (en) * | 2001-09-26 | 2004-01-13 | Yamin Wang | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders |
AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
JP2005529160A (ja) | 2002-05-31 | 2005-09-29 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物 |
WO2004014914A1 (en) | 2002-08-07 | 2004-02-19 | Novartis Ag | Organic compounds as agents for the treatment of aldosterone mediated conditions |
CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
WO2005026164A1 (en) | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Pharmacologically active imidazo[4,5-c]pyridines |
AU2004275718B2 (en) | 2003-09-23 | 2008-02-07 | Merck Sharp & Dohme Corp. | Quinazoline potassium channel inhibitors |
DE602005008416D1 (de) | 2004-03-26 | 2008-09-04 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
JP2008500999A (ja) | 2004-05-28 | 2008-01-17 | シュペーデル・エクスペリメンタ・アーゲー | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
US20080076784A1 (en) | 2004-05-28 | 2008-03-27 | Peter Herold | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors |
CA2568165A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
NZ587547A (en) | 2004-06-24 | 2012-09-28 | Vertex Pharma | Modulators of ATP-Binding Cassette Transporters |
TW200611897A (en) | 2004-07-09 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
WO2007002559A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ras特異的細胞障害性化合物およびその使用法 |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
WO2007116908A1 (ja) | 2006-04-04 | 2007-10-18 | Taiyo Nippon Sanso Corporation | メタン分離方法、メタン分離装置及びメタン利用システム |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
RU2009110442A (ru) | 2006-08-25 | 2010-09-27 | Новартис АГ (CH) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой |
US8143278B2 (en) | 2006-12-18 | 2012-03-27 | Novartis Ag | Organic compounds |
BRPI0721290A2 (pt) | 2006-12-18 | 2014-03-25 | Novartis Ag | Compostos orgânicos |
WO2008076336A2 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | Imidazoles as aldosterone synthase inhibitors |
BRPI0809645A2 (pt) | 2007-03-29 | 2014-09-23 | Novartis Ag | Espoiro-composots heterocíclicos |
US8338406B2 (en) * | 2008-02-22 | 2012-12-25 | Otsuka Pharmaceutical Co., Ltd. | Benzodiazepine compound and pharmaceutical composition |
WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
JP5894161B2 (ja) | 2010-08-25 | 2016-03-23 | ネオファーム カンパニー, リミテッド | 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物 |
EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
JP6018633B2 (ja) | 2011-07-12 | 2016-11-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | アミノメチルキノロン化合物 |
US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
EP2855472B1 (en) | 2012-04-05 | 2016-09-14 | Boehringer Ingelheim International GmbH | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
TW201444558A (zh) | 2013-03-15 | 2014-12-01 | Melinta Therapeutics Inc | 使用喹諾酮類抗生素治療淋病感染的方法 |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AR096022A1 (es) | 2013-04-11 | 2015-12-02 | Basf Se | Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales |
WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
EP3088399A4 (en) | 2013-12-26 | 2017-10-25 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
BR112017003546A2 (pt) | 2014-08-21 | 2017-12-05 | Glaxosmithkline Ip Dev Ltd | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos |
PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/ar unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/es not_active Application Discontinuation
- 2017-10-19 MX MX2019004484A patent/MX2019004484A/es unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/pl unknown
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/lt unknown
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/ja active Active
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/es unknown
- 2017-10-19 CA CA3038624A patent/CA3038624A1/en active Pending
- 2017-10-19 SI SI201731279T patent/SI3529251T1/sl unknown
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en active Application Filing
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/fi active
- 2017-10-19 TW TW106135836A patent/TWI759343B/zh active
- 2017-10-19 RS RS20221152A patent/RS63841B1/sr unknown
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/ko active IP Right Grant
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/hr unknown
- 2017-10-19 BR BR112019007863A patent/BR112019007863A2/pt active Search and Examination
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/hu unknown
- 2017-10-19 ES ES17801105T patent/ES2934234T3/es active Active
- 2017-10-19 PT PT178011052T patent/PT3529251T/pt unknown
- 2017-10-19 CU CU2019000042A patent/CU24599B1/es unknown
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 CR CR20190201A patent/CR20190201A/es unknown
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/zh active Active
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/es unknown
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/es unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/es unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/es unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/ar unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
PH12016502246A1 (en) | Carboxamide derivatives | |
EA201692298A1 (ru) | Производные карбоксамидов | |
PH12020550763A1 (en) | Pyridinone derivatives and their use as selective alk-2 inhibitors | |
PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
EA201991008A1 (ru) | Новые производные нафтиридинона и их применение в лечении аритмии |